LLY

779.86

-1.89%↓

JNJ

152.52

+0.03%↑

ABBV

185.27

-0.73%↓

NVO

68.23

+1.32%↑

UNH

307.35

+1.39%↑

LLY

779.86

-1.89%↓

JNJ

152.52

+0.03%↑

ABBV

185.27

-0.73%↓

NVO

68.23

+1.32%↑

UNH

307.35

+1.39%↑

LLY

779.86

-1.89%↓

JNJ

152.52

+0.03%↑

ABBV

185.27

-0.73%↓

NVO

68.23

+1.32%↑

UNH

307.35

+1.39%↑

LLY

779.86

-1.89%↓

JNJ

152.52

+0.03%↑

ABBV

185.27

-0.73%↓

NVO

68.23

+1.32%↑

UNH

307.35

+1.39%↑

LLY

779.86

-1.89%↓

JNJ

152.52

+0.03%↑

ABBV

185.27

-0.73%↓

NVO

68.23

+1.32%↑

UNH

307.35

+1.39%↑

Search

Verve Therapeutics Inc

Deschisă

11.27 0.63

Rezumat

Modificarea prețului

24h

Curent

Minim

11.2

Maxim

11.28

Indicatori cheie

By Trading Economics

Venit

19M

-31M

Vânzări

20M

33M

EPS

-0.35

Marjă de profit

-94.108

Angajați

274

EBITDA

19M

-35M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+34.34% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

604M

992M

Deschiderea anterioară

10.64

Închiderea anterioară

11.27

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Verve Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 iun. 2025, 11:56 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

17 iun. 2025, 14:02 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know. -- Barrons.com

17 iun. 2025, 12:12 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring 77%. What to Know. -- Barrons.com

17 iun. 2025, 11:01 UTC

Achiziții, Fuziuni, Preluări

This Stock Just Jumped 77% After Eli Lilly Made an Agreed $1.3 Billion Bid -- Barrons.com

17 iun. 2025, 10:47 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly: Total Potential Consideration of Up to $13.50 Per Shr in Cash Without Interest >LLY

17 iun. 2025, 10:47 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly: Considering Also Includes One Non-Tradeable Contingent Value Right Per Shr That Entitles Holder to Receive Up to an Additional $3 Per Shr >LLY

17 iun. 2025, 10:46 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly Will Commence Tender Offer to Acquire All Outstanding Shrs of Verve for Purchase Price of $10.50 Per Shr in Cash >LLY

17 iun. 2025, 10:45 UTC

Achiziții, Fuziuni, Preluări

Lilly To Acquire Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

17 iun. 2025, 09:33 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. -- Barrons.com

Comparație

Modificare preț

Verve Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

34.34% sus

Prognoză pe 12 luni

Medie 15.06 USD  34.34%

Maxim 24 USD

Minim 11 USD

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruVerve Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

10 ratings

4

Cumpărare

6

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

4.1501 / 5.16Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Very Strong Bearish Evidence

Termen lung

Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Verve Therapeutics Inc

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.